CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
Neoadjuvant Immunotherapy with Response-Adapted Treatment vs Standard-Of-Care Treatment For Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)
The Cancer Research Study Coordinator works within a team based structure to coordinate and oversee national, international and cooperative oncology group, multi-centre, multi-modality clinical trials in cancer therapy, prevention and supportive care.
OlympiA: A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.
The Toronto International Sarcoma Symposium 2021 (virtual format) is just around the corner!
This multidisciplinary symposium will be held on April 09, 2021, and includes speakers and participants from Canada as well as from the International Sarcoma community. The keynote speakers are Dr. Andrew Wagner (Dana Farber) and Dr. David Kirsch (Duke). The one day symposium will feature Clinical and Translational Research among other topics, please see the program page for details.
The CCTG CO29 (AGITG CTDNA-08) - Circulating Tumor DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multi-centre Phase II/III Randomised Controlled Study (DYNAMIC III) has been centrally activated.
CCTG is hiring and looking for a Manager, Office of Compliance and Oversight (OCO) and a Quality Leader, Office of Clinical Trials Management (OCTM) to join our team at the central operations office at Queen's University.
CCTG is delighted to announce that Dr. Alexander Wyatt has become the new Correlative Sciences Committee Chair for the CCTG GU disease site committee.
Dr. Wyatt is an Assistant Professor in Urologic Sciences at the University of British Columbia, a Senior Research Scientist at the Vancouver Prostate Centre, and Scientist at the BC Cancer Genome Sciences Centre. He has a PhD in genetics (University of Oxford), and now specializes in human genitourinary cancer genomics and bio informatics
Meet Martina Wood a breast cancer survivor and a member of the CCTG breast committee. Our teams are proud to work with volunteers like Martina who ensure the patient voice is part of our clinical trial development.
